Shares of the cloud security company Zscaler Inc (NASDAQ: ZS), which debuted on the public market in early 2018, are tumbling to their lowest level since February in reaction to the company's fiscal fourth-quarter results.
Bank of America Merrill Lynch analyst Tal Liani reiterated a Neutral rating and reduced the price target from $77 to $65.
Credit Suisse analyst Brad Zelnick maintained an Outperform rating but lowered the price target from $78 to $70.
Wedbush analyst Daniel Ives maintained an Outperform rating but took down the price target from $90 to $80.
Morgan Stanley Harps On Zscaler's Lofty Multiple
Billings growth decelerated sharply for a second straight quarter, likely affecting the trading multiple of shares, Franchi said in a Wednesday note.
The company is likely to be hurt by increasing competition in cloud-based security and the fast-changing nature of the security market, the analyst said.
Investor confidence is likely to be further rattled by the company's commentary on a more unsettled macro environment and the potential for sales changes as a new chief revenue officer takes charge, she said.
That said, Morgan Stanley sees Zscaler as a leader in cloud-based security, with strong Global 2000 customer growth and impressive net dollar retention rates.
"However, with higher sales investments pressuring our near-term FCF estimates, we are trimming our price target to $47, and would await a more attractive entry point to get constructive on ZS."
See also: Wedbush Names 'Best Pure Play' In Cloud Security
BofA: Zscaler Still In Strong Competitive Position
Zscaler's fourth-quarter results exceeded estimates, with gross and operating margin outperformance, Liani said in a Wednesday note.
Yet the first-quarter guidance was mixed and the fiscal year 2020 guidance was subpar, the analyst said.
The company attributed the lackluster guidance to longer sales cycles due to economic uncertainty and the recent hiring of a CRO that shifts billings seasonality from the first half to the second half, he said.
"The stock pared most of its 2019 gains in the last few weeks, yet we believe Zscaler is still in a strong competitive position with market tailwinds in place."
Credit Suisse: Zscaler A Long-term Winner
Zscaler's results were fairly strong, although the magnitude of the revenue beat was not as robust as previous quarters, Zelnick said in a Wednesday note.
The company sees the Office 365, SD-WAN and SI partnerships as large drivers for Zscaler adoption, the analyst said.
ZPA and upsell to the Transformation bundle are still largely untapped opportunities, he said.
Zelnick sees the Zenith Live Conference/Analyst Day due next week as a positive catalyst, with the potential for new product and business announcements.
" ... We remain confident in Zscaler as a long-term winner in clouddelivered security and network transformation."
Wedbush: We Are Not Shying Away From Bullish Thesis
Wedbush said it continues to view Zscaler as "an under-promise, over-deliver story," Ives said in a Wednesday note.
The company has massive tailwinds to its "cloud native network security approach with an expanded product footprint," the analyst said.
"ZS has built a massive technology advantage and a competitive moat that we view as very defensible, despite the constant noise as well as skeptics around the name."
Notwithstanding the earnings-induced weakness, Ives said he is not shying away from the bull thesis, as he believes the company will grow in valuation over the next 12-18 months and regain the Street's confidence as it proves itself again in the fiscal year 2020.
The Price Action
Zscaler shares were tumbling 19.2% to $49.73 at the time of publication Wednesday.
Related Link: Wedbush: Zscaler Delivers Jaw-Dropping Quarter, With Strength Across The Board
Latest Ratings for ZS
|Sep 2019||Maintains||Market Perform|
View More Analyst Ratings for ZS
View the Latest Analyst Ratings
See more from Benzinga
- Alerus Financial IPO: What You Need To Know
- Longbow Upgrades Micron As Memory Market Fundamentals Improve
- The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With 0M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.